Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
ABL1 p.T315I,
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|